X2R60WA
Replacement Upper Extremity Artery, Left to New Technology Group 10 with Bioengineered Human Acellular Vessel, Open Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | 2 Cardiovascular System |
| Operation | R Replacement |
| Body Part | 6 Upper Extremity Artery, Left |
| Approach | 0 Open |
| Device | W Bioengineered Human Acellular Vessel |
| Qualifier | A New Technology Group 10 |
Operation Definition
Putting in or on biological or synthetic material that physically takes the place and/or function of all or a portion of a body part
Procedure Overview
This family involves implanting biological or synthetic material that takes over the physical structure and function of all or part of a cardiovascular structure, using a device recently designated as new technology. A well-known example is a transcatheter aortic valve replacement performed with a next-generation valve system delivered through a catheter rather than open surgery, taking over the role of the patient's diseased native valve. These procedures are typically offered to patients whose anatomy or surgical risk makes the newer device or delivery approach preferable to established alternatives.
The underlying clinical rationale mirrors any replacement procedure: the native structure has failed or degraded to the point that its function must be physically taken over by the substitute material.
Anatomy & Axis Detail
Upper Extremity Artery, Left
The left upper extremity artery shares the same clinical considerations as its right-sided counterpart, with replacement most often driven by trauma, aneurysmal degeneration, infection, or exhausted dialysis access options. Coding this under New Technology typically points to a bioengineered or acellular tissue-derived graft used in place of the diseased arterial segment, valued for reduced susceptibility to infection compared with prosthetic material and for its capacity to be recannulated repeatedly for dialysis. Because these grafts are positioned as a durable substitute rather than simply routed around a blockage, the procedure must involve actual excision and replacement of the artery segment. Laterality should be verified against the operative report, as the technique and rationale otherwise mirror the right-sided procedure.
Approach: Open
Open approach in New Technology denotes access to the target site through a surgical incision that exposes the body part directly to view and instrumentation. It stands apart from percutaneous and endoscopic approaches, which achieve access through small punctures or existing openings rather than a deliberate surgical opening of tissue.
Device / Substance / Technology: Bioengineered Human Acellular Vessel
This value denotes a bioengineered vascular conduit grown from human cells to be acellular before implantation, used as a vessel substitute such as for hemodialysis access or peripheral bypass when autologous vein is unsuitable. It is distinguished from synthetic grafts by its biologic, tissue-derived composition and from cellular tissue substitutes by lacking living donor cells at implantation. This design aims to reduce infection risk while allowing gradual host cell repopulation.
Qualifier: New Technology Group 10
New Technology Group 10 flags a procedure as part of the 2023 batch of add-on codes recognized under the New Technology section. The value itself carries no information about the device or drug involved; that comes from the table, body part, and approach values alongside it. Coders should not confuse it with Group 9 or Group 11, which cover the cohorts approved in the years immediately before and after.
Coding & Documentation
Coders need documentation identifying the specific replacement device by name, the approach used to deliver it, and confirmation that it physically substitutes for the body part rather than merely reinforcing it. A common error is assigning the standard Cardiovascular section Replacement code when the device actually qualifies for New Technology status, or the reverse, using a New Technology code for a device whose table entry has since been retired or superseded. Coders should also verify the qualifier correctly reflects the number of devices or valve components involved when multiple components are placed in the same session.
Commonly Confused With
This is often confused with Supplement, where the deciding question is whether the material replaces the structure entirely or simply reinforces and augments an existing structure that is left largely in place. It is also distinguished from the standard-section valve or vessel replacement codes purely by the device's inclusion in the New Technology table for the applicable code set year.